Effects of circadian disruption on neurobehavioural and physiological variables in patients with respiratory disorders and healthy controls.

Woolcock Institute of Medical Research0 个研究点目标入组 40 人开始时间: 2005年8月5日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•OSA: Untreated subjects with moderate to severe OSA (RDI > 30).
•Asthma: Asthmatic subjects (ATS Criteria) will be recruited from asthma clinics associated with AIs. We will use clinic patients (current non-smokers and minimal smoking history)with moderate to severe asthma based on NAC guidelines i.e. those requiring short acting beta agonists 3 or more days week or with nocturnal symptoms more than once per fortnight.
•Controls: We will recruit healthy controls.

•OSA: use of alcohol> 40gm/day, psychotropic medication, intercurrent asthma, other unstable medical conditions or evidence of clinically significant awake respiratory failure.
•Asthma:We will exclude subjects on long-acting bronchodilators (salmeterol, formoterol, tiotropium and theophylline). Inhaled corticosteroids will be held constant from screening into studies and use of short acting beta agonists will be permitted and monitored during protocols.
•Controls: similar exclusion criteria as for the OSA and asthma subjects
•Subjects with the presence of asthma (ATS criteria) and OSA will be excluded. The absence of OSA will be determined using a validated nocturnal respiratory monitor over 2 nights (Autoset T, ResMed).

发起方